NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer - PharmaTimes Imfinzi and Imjudo combination recommended as first-line treatment

#oncology #NICE #AstraZeneca #dualimmunotherapy #advancedlivercancer #livercancer #Imfinzi #durvalumab #Imjudo #tremelimumab #Advancedhepatocellularcarcinoma #unresectablehepatocellularcarcinoma #HCC #NICEapproval #STRIDEregimen #primarylivercancer #BritishLiverTrust
zurl.co/M3ftp